公开(公告)号：US20220220508A1

公开(公告)日：2022-07-14

申请号：US17542219

申请日：2021-12-03

Applicant: Scribe Therapeutics Inc.

Inventor： Benjamin OAKES ,  Sean HIGGINS ,  Hannah SPINNER ,  Sarah DENNY ,  Brett T. STAAHL ,  Kian TAYLOR ,  Katherine BANEY ,  Isabel COLIN ,  Maroof ADIL

IPC: C12N15/90 ,  C12N9/22 ,  C12N15/11 ,  C12N15/86

Abstract: Provided herein are engineered CasX systems and components thereof, including variant CasX proteins and variant guide nucleic acids (gNAs). The variant CasX proteins and variant gNAs of the disclosure display at least one improved characteristic when compared to a reference CasX protein or reference gNA of the disclosure. In some instances, the variants have one or more improved CasX ribonucleoprotein complex functions. Also provided are methods of making and using said variants.

公开(公告)号：US20240360474A1

公开(公告)日：2024-10-31

申请号：US18608127

申请日：2024-03-18

Applicant: Scribe Therapeutics Inc.

Inventor： Katherine BANEY ,  Isabel COLIN ,  Cécile FORTUNY ,  Sean HIGGINS ,  Suraj MAKHIJA ,  Brett T. STAAHL ,  Maroof ADIL ,  Benjamin OAKES ,  Addison WRIGHT ,  Angus SIDORE ,  Manuel MOHR ,  Sarah DENNY

IPC: C12N15/86 ,  C12N9/22 ,  C12N15/11

CPC classification number: C12N15/86 ,  C12N9/22 ,  C12N15/111 ,  C07K2319/09 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2750/14122 ,  C12N2750/14123 ,  C12N2750/14143 ,  C12N2750/14152

Abstract: Provided herein are compositions and methods for use of self-inactivating recombinant vectors (SIRV) encoding Class 2 Type V and guide ribonucleic acid (gRNA) sequences useful for nucleic acid sequence editing, and including self-inactivating components. The SIRV may be delivered to cells as part of an AAV vector to target a gene of interest.

公开(公告)号：US20220348925A1

公开(公告)日：2022-11-03

申请号：US17641426

申请日：2020-09-09

Applicant: Scribe Therapeutics Inc.

Inventor： Benjamin OAKES ,  Sean HIGGINS ,  Hannah SPINNER ,  Sarah DENNY ,  Brett T. STAAHL ,  Kian TAYLOR ,  Katherine BANEY ,  Isabel COLIN ,  Maroof ADIL ,  Cole URNES

IPC: C12N15/113 ,  C12N15/10 ,  C12N9/22 ,  C12N9/06 ,  A61P25/28

Abstract: Provided herein are CasX:gNA systems comprising CasX polypeptides, guide nucleic acids (gNA), and optionally donor template nucleic acids useful in the modification of a SOD1 gene. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations in the SOD1 protein or the SOD1 regulatory element. Also provided are methods of using such CasX:gNA systems to modify cells having such mutations and utility in methods of treatment of a subject with a SOD1-related disease.

公开(公告)号：US20220090036A1

公开(公告)日：2022-03-24

申请号：US17483692

申请日：2021-09-23

Applicant: Scribe Therapeutics Inc.

Inventor： Benjamin OAKES ,  Sean HIGGINS ,  Hannah SPINNER ,  Sarah DENNY ,  Brett T. STAAHL ,  Kian TAYLOR ,  Katherine BANEY ,  Isabel COLIN ,  Maroof ADIL ,  Cole URNES

IPC: C12N9/22 ,  C12N15/11 ,  C12N15/90

Abstract: Provided herein are CasX:gNA systems comprising CasX polypeptides, guide nucleic acids (gNA), and optionally donor template nucleic acids useful in the modification of a SOD1 gene. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations in the SOD1 protein or the SOD1 regulatory element. Also provided are methods of using such CasX:gNA systems to modify cells having such mutations and utility in methods of treatment of a subject with a SOD1-related disease.

公开(公告)号：US20220081681A1

公开(公告)日：2022-03-17

申请号：US17533997

申请日：2021-11-23

Applicant: Scribe Therapeutics Inc.

Inventor： Benjamin OAKES ,  Sean HIGGINS ,  Hannah SPINNER ,  Sarah DENNY ,  Brett T. STAAHL ,  Kian TAYLOR ,  Katherine BANEY ,  Isabel COLIN ,  Maroof ADIL

IPC: C12N9/22 ,  C12N15/11

Abstract: Provided herein are engineered proteins. In some embodiments, the engineered proteins comprise a RuvC DNA cleavage domain comprising one or more modifications, relative to a naturally occurring domain. In some embodiments, the engineered proteins comprise a chimeric domain, for example a chimeric helical I domain. In some embodiments, the engineered proteins are chimeric proteins, comprising at least two domains, each domain derived from a different source, for example derived from SEQ ID NO: 1 and SEQ ID NO: 2. Also provided are systems comprising these engineered proteins, and methods of making and using said engineered proteins.